Recursion Pharmaceuticals is trading at $3.44 (-5.37%), with the decline appearing aligned with broader risk-off trading.
- No clear company-specific announcement or catalyst was identified for September 8, 2026.
- Recursion’s latest disclosed updates were its August 4 conference announcement and August 5 earnings report.
- The S&P 500 is down 0.56%; oil-price gains, Middle East tensions, and stronger jobs data are weighing on sentiment. Trading-volume details were unavailable.